Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.75, $0.23 worse than the analyst estimate of $1.98. Revenue for the quarter came in at $11.2 billion versus the consensus estimate of $11.81 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2023 EPS of $7.35-$7.65, versus the consensus of $7.99.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.